Apellis Pharmaceuticals Inc (NASDAQ:APLS) CEO Cedric Francois sold 5,000 shares of Apellis Pharmaceuticals stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $34.46, for a total transaction of $172,300.00. Following the completion of the transaction, the chief executive officer now owns 1,083,079 shares in the company, valued at $37,322,902.34. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Cedric Francois also recently made the following trade(s):
- On Tuesday, September 15th, Cedric Francois sold 5,000 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.96, for a total transaction of $154,800.00.
- On Thursday, August 20th, Cedric Francois sold 3,457 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $103,710.00.
- On Tuesday, August 18th, Cedric Francois sold 1,543 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $30.00, for a total value of $46,290.00.
Shares of NASDAQ:APLS opened at $34.81 on Friday. The company has a current ratio of 14.72, a quick ratio of 14.72 and a debt-to-equity ratio of 1.50. The firm has a market capitalization of $2.63 billion, a PE ratio of -5.17 and a beta of 1.15. Apellis Pharmaceuticals Inc has a 1-year low of $16.85 and a 1-year high of $45.04. The business’s 50 day moving average is $31.29 and its 200-day moving average is $30.98.
Apellis Pharmaceuticals (NASDAQ:APLS) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.57) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.34) by ($0.23). On average, sell-side analysts predict that Apellis Pharmaceuticals Inc will post -7.02 EPS for the current year.
APLS has been the subject of several analyst reports. Citigroup cut their target price on shares of Apellis Pharmaceuticals from $56.00 to $54.00 and set a “buy” rating for the company in a research note on Tuesday, June 30th. BidaskClub cut Apellis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, July 31st. ValuEngine upgraded Apellis Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Stifel Nicolaus initiated coverage on Apellis Pharmaceuticals in a report on Monday, August 31st. They issued a “buy” rating and a $40.00 price target for the company. Finally, Roth Capital initiated coverage on Apellis Pharmaceuticals in a research report on Monday, July 20th. They issued a “buy” rating and a $50.00 target price on the stock. One research analyst has rated the stock with a sell rating, six have assigned a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $50.14.
A number of large investors have recently bought and sold shares of the business. Parametric Portfolio Associates LLC grew its stake in Apellis Pharmaceuticals by 4.3% in the first quarter. Parametric Portfolio Associates LLC now owns 9,950 shares of the company’s stock valued at $267,000 after acquiring an additional 409 shares during the period. Prudential Financial Inc. raised its holdings in Apellis Pharmaceuticals by 0.9% during the second quarter. Prudential Financial Inc. now owns 89,254 shares of the company’s stock worth $2,915,000 after acquiring an additional 792 shares in the last quarter. Alliancebernstein L.P. raised its holdings in Apellis Pharmaceuticals by 2.0% during the first quarter. Alliancebernstein L.P. now owns 75,200 shares of the company’s stock worth $2,015,000 after acquiring an additional 1,500 shares in the last quarter. State Board of Administration of Florida Retirement System raised its holdings in Apellis Pharmaceuticals by 11.0% during the second quarter. State Board of Administration of Florida Retirement System now owns 22,695 shares of the company’s stock worth $741,000 after acquiring an additional 2,248 shares in the last quarter. Finally, Advisor Group Holdings Inc. bought a new stake in Apellis Pharmaceuticals during the first quarter worth about $68,000. 80.80% of the stock is owned by hedge funds and other institutional investors.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types of glomerular diseases, such as C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.